menu
    • menu
    [{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Cerebral","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Cerebral"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Lightswitch Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Lightswitch Capital"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ALTO-102","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ InVivium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ InVivium Capital"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ALTO-300","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ALTO-203","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ALTO-101","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alto Neuroscience","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"12","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alto Neuroscience \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Alto Neuroscience

    Menu

    Alto Neuroscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Wellcome Trust

                            Deal Size : $11.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Alto Neuroscience Gets Trust Funding for ALTO-100 in Bipolar Depression

                            Details : The fund will used to advance the clinical development of lead candidate ALTO-100 through a Phase 2b study in patients with bipolar depression characterized by a cognitive biomarker.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Wellcome Trust

                            Deal Size : $11.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alto Neuroscience Completes Enrollment in Phase 2b Study of ALTO-100 for Depression

                            Details : ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF), which is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 16, 2024

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-101

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alto Neuroscience Reports Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor

                            Details : ALTO-101 is a novel PDE4 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of cognitive impairment associated with schizophrenia.

                            Brand Name : ALTO-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 23, 2024

                            Lead Product(s) : ALTO-101

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-203

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alto Neuroscience Begins Phase 2 Study of ALTO-203 for Major Depressive Disorder

                            Details : ALTO-203 is a novel small molecule histamine H3 receptor inverse agonist, which is being developed for the treatment of patients with MDD and elevated anhedonia.

                            Brand Name : ALTO-203

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 03, 2024

                            Lead Product(s) : ALTO-203

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $147.9 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alto Neuroscience Closes Upsized IPO with Underwriters’ Option Exercise

                            Details : Net proceeds will advance ALTO-100, targeting brain-derived neurotrophic factor (BDNF) for treating major depressive disorder and PTSD, developed by Alto Neuroscience.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 06, 2024

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $147.9 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $128.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alto Neuroscience Announces Pricing of Upsized Initial Public Offering

                            Details : Net proceeds will advance ALTO-100, targeting brain-derived neurotrophic factor (BDNF) for treating major depressive disorder and PTSD, developed by Alto Neuroscience.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 01, 2024

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $128.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alto Neuroscience preps IPO to Push CNS Therapies Through Clinic

                            Details : The net proceeds will advance clinical development of ALTO-100, targeting BDNF for treating major depressive disorder and post-traumatic stress disorder by Alto Neuroscience.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 16, 2024

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-300

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder

                            Details : ALTO-300 is an investigational small molecule drug candidate, which is a melatonin receptor agonist. currently, it is being evaluated under clinical development with patients suffering related to major depressive disorder.

                            Brand Name : ALTO-300

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 04, 2023

                            Lead Product(s) : ALTO-300

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : InVivium Capital

                            Deal Size : $45.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing

                            Details : The funds will be used to support ongoing and planned clinical development of the Company's late-stage CNS product candidates, including ALTO-100 currently in Phase II for Major Depressive Disorder.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 21, 2023

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : InVivium Capital

                            Deal Size : $45.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alto Neuroscience

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-100 in Post-Traumatic Stress Disorder

                            Details : The Phase 2 study leveraged Alto’s Precision Psychiatry Platform™ to identify likely drug responders based on an understanding of biological heterogeneity in depression and ALTO-100’s novel mechanism.

                            Brand Name : ALTO-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : ALTO-100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth